Literature DB >> 22289702

Prostate cancer: making the switch from LHRH antagonist to LHRH agonist.

Judd W Moul.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22289702     DOI： 10.1038/nrurol.2012.5

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Twenty-five year evolution of medical hormonal therapy for prostate cancer.

Authors:  Judd W Moul
Journal:  BJU Int       Date:  2009-01       Impact factor: 5.588

2.  A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.

Authors:  D McLeod; N Zinner; K Tomera; D Gleason; N Fotheringham; M Campion; M B Garnick
Journal:  Urology       Date:  2001-11       Impact factor: 2.649

3.  New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.

Authors:  Robert Dreicer; Dean F Bajorin; David G McLeod; Daniel P Petrylak; Judd W Moul
Journal:  Urology       Date:  2011-11       Impact factor: 2.649

Review 4.  Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.

Authors:  Charles J Ryan; Donald J Tindall
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

5.  A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

Authors:  E David Crawford; Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Fritz Schröder; Neal Shore; Judd W Moul; Jens-Kristian Jensen; Tine Kold Olesen; Bo-Eric Persson
Journal:  J Urol       Date:  2011-07-23       Impact factor: 7.450

6.  New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.

Authors:  Marc B Garnick; Nicolas Mottet
Journal:  BJU Int       Date:  2011-11-16       Impact factor: 5.588

7.  Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

Authors:  Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Fritz Schröder; Neal Shore; E David Crawford; Judd Moul; Jens-Kristian Jensen; Tine Kold Olesen; Bo-Eric Persson
Journal:  Eur Urol       Date:  2009-11-20       Impact factor: 20.096

Review 8.  Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer.

Authors:  Pierre Mongiat-Artus; Pierre Teillac
Journal:  Expert Opin Pharmacother       Date:  2004-10       Impact factor: 3.889

9.  The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Authors:  Laurence Klotz; Laurent Boccon-Gibod; Neal D Shore; Cal Andreou; Bo-Eric Persson; Per Cantor; Jens-Kristian Jensen; Tine Kold Olesen; Fritz H Schröder
Journal:  BJU Int       Date:  2008-12       Impact factor: 5.588

10.  Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

Authors:  Fritz H Schröder; Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Neal D Shore; E David Crawford; Judd Moul; Tine Kold Olesen; Bo-Eric Persson
Journal:  BJU Int       Date:  2009-11-13       Impact factor: 5.588
  10 in total
  4 in total

1.  Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.

Authors:  A Dragomir; J Rocha; M Vanhuyse; F L Cury; W Kassouf; J Hu; A G Aprikian
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

2.  Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.

Authors:  Alice Dragomir; Daniela Dinea; Marie Vanhuyse; Fabio L Cury; Armen G Aprikian
Journal:  BMC Health Serv Res       Date:  2014-06-13       Impact factor: 2.655

Review 3.  Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.

Authors:  Frank Kunath; Hendrik Borgmann; Anette Blümle; Bastian Keck; Bernd Wullich; Christine Schmucker; Danijel Sikic; Catharina Roelle; Stefanie Schmidt; Amr Wahba; Joerg J Meerpohl
Journal:  BMJ Open       Date:  2015-11-13       Impact factor: 2.692

4.  Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients.

Authors:  Juan Morote; Imma Comas; Roser Ferrer; Jacques Planas; Anna Celma; Lucas Regis
Journal:  J Biomed Sci       Date:  2017-10-22       Impact factor: 8.410
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.